We have a vision

By 2050, the number of people suffering from Alzheimer’s disease will have tripled, affecting a projected 13.8 million people in the US alone. Early detection of this horrible disease is crucial. We’re focused on a solution.

About Us

At Optina Diagnostics we’re focused on the development of technology for the early detection of disease through the eye.

With a first application in the diagnosis of Alzheimer’s disease, our technology highlights retinal amyloid deposits, a key biomarker of this disease.

The solution to a cure for Alzheimer’s begins with the early detection of the disease in order to treat it before irreversible damage occurs. This is an important step.

The Optina Diagnostic retinal imaging test involves a scan of the retina, using equipment and technique that is similar to the fundus photography, which is already being used by ophthalmologists to diagnose retinal diseases.

The Optina Diagnostic test scans the retina and the results are immediately sent to a cloud server to be analyzed by Optina’s proprietary software that efficiently identifies whether amyloid plaque deposits are present.

Currently, the diagnosis of Alzheimer’s relies on a variety of neurobehavioral tests that are subjective, as well as PET scans that are both expensive and inconvenient.

Driven to impact every segment of the healthcare industry – from researchers to clinicians and pharmaceutical companies – Optina Diagnostics’ vision is to revolutionize the way that Alzheimer’s is diagnosed.

Our research camera is currently sold to academic centres where it is being received with great acclaim.

Worldwide, nearly 44 million
people have Alzheimer’s or
a related dementia.

The experts

Optina Diagnostics is made up of a driven and dynamic team of experts in the areas of business development, research, and finance.
team

David Lapointe, M. Sc.

President and CEO

Chantal Miklosi

CFO

Jean-Philippe Sylvestre, ing., M.Sc., Ph.D.

CTO

Claudia Chevrefils, ing., Ph.D.

CIO

Faten M’hiri, Ph.D.

Scientific Team

Reza Jafari, Ph.D.

Scientific Team

Marie-Andrée Tremblay, ing.

Scientific Team

Anne-Marie Bédard

Clinical Study Manager

Sébastien Blais Ouellette, Ph.D.

Board of Directors

Jean Daniel Arbour

Board of Directors